JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB214050

Anti-Osteopontin antibody [EPR21139-316]

  • BOND RX™ Validated
  • RabMAb
  • Recombinant
  • 20ul selling size
  • What is this?

4

(1 Review)

|

(92 Publications)

Anti-Osteopontin antibody [EPR21139-316] (ab214050) is a rabbit monoclonal antibody detecting Osteopontin in Western Blot, IP, IHC-P. Suitable for Human.

- Biophysical QC for unrivalled batch-batch consistency
- Over 40 publications

View Alternative Names

BNSP, OPN, PSEC0156, SPP1, Osteopontin, Bone sialoprotein 1, Nephropontin, Secreted phosphoprotein 1, Urinary stone protein, Uropontin, SPP-1

8 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Osteopontin antibody [EPR21139-316] (AB214050)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Osteopontin antibody [EPR21139-316] (AB214050)

Immunohistochemical analysis of paraffin-embedded human kidney tissue labeling Osteopontin with ab214050 at 1/2000 dilution, followed by Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) Ready to use. Cytoplasmic staining in distal tubules of human kidney (PMID : 17938278), performed on a Leica Biosystems BOND® RX instrument. Counter stained with hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.

Perform heat-mediated antigen retrieval with sodium citrate buffer (pH 6.0, epitope retrieval solution 1) for 10 minutes.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Osteopontin antibody [EPR21139-316] (AB214050)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Osteopontin antibody [EPR21139-316] (AB214050)

Immunohistochemical analysis of paraffin-embedded human liver tissue labeling Osteopontin with ab214050 at 1/2000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use. Cytoplasmic staining in bile ducts of human liver (PMID : 16221502). Counter stained with hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.

Perform heat-mediated antigen retrieval using ab93684 (Tris/EDTA buffer, pH 9.0).

Immunoprecipitation - Anti-Osteopontin antibody [EPR21139-316] (AB214050)
  • IP

Supplier Data

Immunoprecipitation - Anti-Osteopontin antibody [EPR21139-316] (AB214050)

Osteopontin was immunoprecipitated from 0.35 mg of human kidney lysate with ab214050 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab214050 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/5,000 dilution

Lane 1 : Human kidney lysate 10 μg (Input).

Lane 2 : ab214050 IP in human kidney lysate.

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab214050 in human kidney lysate.

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 3 minutes.

The multiple bands observed are likely due to expression of different isoforms, as well as glycosylation (PMID : 8761944; PMID : 11375993; PMID : 8535240; PMID : 12890718).

All lanes:

Immunoprecipitation - Anti-Osteopontin antibody [EPR21139-316] (ab214050)

Predicted band size: 35 kDa

false

Western blot - Anti-Osteopontin antibody [EPR21139-316] (AB214050)
  • WB

Supplier Data

Western blot - Anti-Osteopontin antibody [EPR21139-316] (AB214050)

Blocking/Dilution buffer : 5% NFDM/TBST.

The multiple bands observed are likely due to expression of different isoforms, as well as glycosylation (PMID : 8761944; PMID : 11375993; PMID : 8535240; PMID : 12890718).

The identity of the 90kDa band is unknown.

All lanes:

Western blot - Anti-Osteopontin antibody [EPR21139-316] (ab214050) at 1/1000 dilution

Lane 1:

Human urine at 20 µg

Lane 2:

Human fetal kidney lysate at 10 µg

Secondary

Lane 1:

Western blot - VeriBlot for IP Detection Reagent (HRP) (<a href='/en-us/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/1000 dilution

Lane 2:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 35 kDa

Observed band size: 45 kDa,60 kDa,70 kDa

false

Exposure time: 26s

Western blot - Anti-Osteopontin antibody [EPR21139-316] (AB214050)
  • WB

Lab

Western blot - Anti-Osteopontin antibody [EPR21139-316] (AB214050)

In Western blot, anti-GAPDH antibody (ab181602) loading control staining at 1/1000000 dilution.

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

Low expressing sample : MCF7 (PMID : 16288209); PANC-1 (PMID : 34572536).

All lanes:

Western blot - Anti-Osteopontin antibody [EPR21139-316] (ab214050) at 1/1000 dilution

Lane 1:

A549 (human lung carcinoma epithelial cell) whole cell lysate at 20 µg

Lane 2:

NCI-H460 (human Large Cell Lung Cancer epithelial cell) whole cell lysate at 20 µg

Lanes 3 - 4:

NCI-H1299 (human lung carcinoma epithelial cell) whole cell lysate at 20 µg

Lane 5:

MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Lane 6:

PANC-1 (human pancreatic epithelioid carcinoma epithelial cell) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Observed band size: 36 kDa

false

Exposure time: 80s

Western blot - Anti-Osteopontin antibody [EPR21139-316] (AB214050)
  • WB

Supplier Data

Western blot - Anti-Osteopontin antibody [EPR21139-316] (AB214050)

Blocking and diluting buffer concentration : 5% NFDM/TBST.

We suggest treating cells with BFA which inhibits protein secretion.

All lanes:

Western blot - Anti-Osteopontin antibody [EPR21139-316] (ab214050) at 1/1000 dilution

Lane 1:

Untreated HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg

Lane 2:

HepG2 treated with 300ng/ml BFA for 3h whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 35 kDa

Observed band size: 60 kDa

false

Exposure time: 60s

Western blot - Anti-Osteopontin antibody [EPR21139-316] (AB214050)
  • WB

Supplier Data

Western blot - Anti-Osteopontin antibody [EPR21139-316] (AB214050)

Blocking/Dilution buffer : 5% NFDM/TBST.

The his-tagged recombinant protein was produced in a mammalian expression system, thereby allowing it to be post-translationally modified.

All lanes:

Western blot - Anti-Osteopontin antibody [EPR21139-316] (ab214050) at 1/1000 dilution

All lanes:

Human Osteopontin recombinant protein (aa17-300) produced in a mammalian expression at 0.01 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 35 kDa

Observed band size: 60-65 kDa

false

Exposure time: 26s

Western blot - Anti-Osteopontin antibody [EPR21139-316] (AB214050)
  • WB

CiteAb

Western blot - Anti-Osteopontin antibody [EPR21139-316] (AB214050)

Osteopontin western blot using anti-Osteopontin antibody [EPR21139-316] ab214050. Publication image and figure legend from Chen, P., Chen, Y., et al., 2019, Aging (Albany NY), PubMed 31449494.

ab214050 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab214050 please see the product overview.

Hub proteins and potential pathway proteins were increased in AS plaques, especially in tissue sections of ruptured plaques. (A) Detection of hub proteins (SPP1, MMP9, CCL4, and CCL18) and potential pathway proteins (PPARγ, C/EBP and FABP4) in ruptured plaques and adjacent normal tissues by western blots. β-actin was used as a loading control. Bands were quantified with ImageJ software. (B) Line chart showing IOD/area of proteins in immunoblot analysis. Red squares represent AS plaques, and the green circles indicate adjacent normal tissues. The different colored lines represent the trend of protein expression. (C, D) H&E (a) and Movat (b and c, low and high power) staining and immunoperoxidase antibody staining using anti-CD68 (d), anti-SPP1 (e), anti-MMP9 (f), anti-CCL4 (g), and anti-CCL18 (h). Ca, calcification; PR, plaque rupture; Th, thrombus.

false

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR21139-316

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB, IHC-P, IP

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

<p>Osteopontin is a secretory protein, to allow the detection of Osteopontin in cell lysate, we suggest treating cells with BFA which inhibits protein secretion.</p>

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/2000", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval before commencing with IHC staining protocol.", "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "1/50", "ICCIF-species-notes": "<p></p>" }, "Recombinant fragment - Human": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Product details

Product Specifications
Anti-Osteopontin antibody [EPR21139-316] (ab214050) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P, IP, WB in human samples.
Anti-Osteopontin antibody [EPR21139-316] (ab214050) specifically detects Osteopontin (UniProt ID: P10451; Molecular weight: 34kDa) and is sold in 100 µL and 1 mL selling sizes.

Quality and Validation
Abcam's high quality manufacturing and validation processes ensure Anti-Osteopontin antibody [EPR21139-316] (ab214050) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-Osteopontin antibody [EPR21139-316] (ab214050) has been cited over 40 times in peer reviewed journals and is trusted by the scientific community.


Related Products
Antibody clone EPR21139-316 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 488, Alexa Fluor® 594, Alexa Fluor® 647, Alexa Fluor® 555 (ab282004, ab282279, ab283696, ab309603).

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Osteopontin also known as OPN or secreted phosphoprotein 1 (SPP1) is a glycoprotein with a molecular weight of approximately 44 to 75 kDa depending on its post-translational modifications. Osteopontin is characteristically expressed in bone but is also present in various body tissues including kidney liver and immune system cells. This multifunctional protein interacts with cell surface receptors such as integrins and CD44 playing an important role in cell signaling and extracellular matrix interactions. Researchers often study it using osteopontin western blot or osteopontin ELISA kit to understand its expression patterns and roles.
Biological function summary

Osteopontin affects cell adhesion migration and survival. It does not form part of a known large complex but interacts closely with its integrin receptors. Osteopontin modulates immune responses and aids in bone remodeling by affecting osteoclast and osteoblast functions. It is also influential in inflammation processes where it orchestrates the recruitment and activation of macrophages. The osteopontin function is significant in both physiological processes and pathologies marking it as an important protein to study in numerous biological contexts.

Pathways

Osteopontin is integral to both the bone remodeling and immune response pathways. It collaborates with proteins like osteocalcin and matrix metalloproteinases within these processes. In the bone remodeling pathway osteopontin mediates communication between osteoclasts and osteoblasts impacting bone resorption and formation. In the immune response pathway it coordinates with cytokines such as interleukin-6 to modulate immune cell activities. Its roles in these pathways indicate its multifunctional nature and its impact across different biological systems.

Osteopontin links to cancer and cardiovascular diseases. It facilitates tumor progression and metastasis by interacting with proteins such as vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9). In cardiovascular diseases osteopontin influences atherosclerosis development through interactions with inflammatory cytokines and contributes to plaque stability. These disease associations highlight the importance of osteopontin as both a therapeutic target and a biomarker for disease progression and prognosis.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Major non-collagenous bone protein that binds tightly to hydroxyapatite. Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction.. Acts as a cytokine involved in enhancing production of interferon-gamma and interleukin-12 and reducing production of interleukin-10 and is essential in the pathway that leads to type I immunity.
See full target information SPP1

Publications (92)

Recent publications for all applications. Explore the full list and refine your search

Nature cancer : PubMed40854985

2025

Spatiotemporal analyses of the pan-cancer single-cell landscape reveal widespread profibrotic ecotypes associated with tumor immunity.

Applications

Unspecified application

Species

Unspecified reactive species

Ya Han,Lele Zhang,Dongqing Sun,Guangxu Cao,Yuting Wang,Jiali Yue,Junjie Hu,Zhonghua Dong,Fang Li,Taiwen Li,Peng Zhang,Qiu Wu,Chenfei Wang

Nature communications 16:6770 PubMed40695827

2025

Metabolism archetype cancer cells induce protumor TREM2 macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Tianhao Chu,Guiqi Zhu,Zheng Tang,Weifeng Qu,Rui Yang,Haiting Pan,Yi Wang,Ruilin Tian,Leilei Chen,Zhiqi Guan,Yichao Bu,Qianfu Zhao,Jiafeng Chen,Shengwei Mao,Yuan Fang,Jun Gao,Xiaoling Wu,Jian Zhou,Weiren Liu,Dan Ye,Jia Fan,Yinghong Shi

Nature communications 16:6769 PubMed40695833

2025

DSS1 inhibits autophagy to activate epithelial-mesenchymal transition in a pro-metastatic niche of renal cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoyu Chen,Qingyuan Liu,Jingxian Wu,Pengfei Zhou,Mingming Zhao,Jing Song

BMC oral health 25:1227 PubMed40696336

2025

Three-dimensional scaffold-free periodontal ligament stem cell pellets for alveolar ridge preservation: an in vitro and in vivo study.

Applications

Unspecified application

Species

Unspecified reactive species

Xiang Liang,Zhou Zhang,Siya Fang,Sadam Ahmed Elayah,Le Bai,Sina Ahmadi,Jin Liu,Fangfang Xu,Ying Han,Junbo Tu,Sijia Na

Cancers 17: PubMed40647383

2025

Subclassification-Specific Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Implications for Appropriate Pharmacotherapy.

Applications

Unspecified application

Species

Unspecified reactive species

Masahiko Kinoshita,Yasunori Sato,Shoji Kubo,Hiroji Shinkawa,Kenjiro Kimura,Kohei Nishio,Ryota Tanaka,Shigeaki Kurihara,Takeaki Ishizawa

BMC biotechnology 25:55 PubMed40597198

2025

Assessing bone regeneration potential of 3D scaffold-free cell pellets from periodontal ligament and bone marrow stem cells.

Applications

Unspecified application

Species

Unspecified reactive species

Xiang Liang,Yuxin Gong,Le Bai,Sina Ahmadi,Ming Yu,Zhou Zhang,Siya Fang,Fangfang Xu,Weiqi Wang,Junbo Tu,Sijia Na

Scientific reports 15:19979 PubMed40481141

2025

EIF4A3 enhances the viability, invasion and osteogenic differentiation of BMSCs via the USP53/SMAD5 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Gang Cheng,Xiaoling Yang,Yongtao Tang,Changjun Wu,Zulin Tang,Siqi Wei

Frontiers in immunology 16:1568556 PubMed40453096

2025

Case Report: FAP fibroblasts and SPP1 macrophages in SMARCA2-deficient while SMARCA4-preserved poorly differentiated lung adenocarcinoma: two case reports and multi-omics analysis.

Applications

Unspecified application

Species

Unspecified reactive species

Zhaoxuan Wang,Junying Wang,Shengmin Wang,Weijiao Xu,Yixiang Zhang

Nature communications 16:5007 PubMed40442104

2025

Single-cell and spatial transcriptome analyses reveal tumor heterogeneity and immune remodeling involved in pituitary neuroendocrine tumor progression.

Applications

Unspecified application

Species

Unspecified reactive species

Wan Su,Zhang Ye,Jifang Liu,Kan Deng,Jinghua Liu,Huijuan Zhu,Lian Duan,Chen Shi,Linjie Wang,Yuxing Zhao,Fengying Gong,Yi Zhang,Bo Hou,Hui You,Feng Feng,Qing Ling,Yu Xiao,Yongdong Guo,Wenyi Fan,Sumei Zhang,Zixin Zhang,Xiaomin Hu,Yong Yao,Chunhong Zheng,Lin Lu

Journal of cell communication and signaling 19:e70016 PubMed40401147

2025

ELAVL1 promotes ferroptosis via the TRIM21/HOXD8 axis to inhibit osteogenic differentiation in congenital pseudoarticular tibia-derived mesenchymal stem cells.

Applications

Unspecified application

Species

Unspecified reactive species

Weihua Ye,Zheng Liu,Yaoxi Liu,Han Xiao,Qian Tan,An Yan,Guanghui Zhu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com